BioCanCell Announces Updated Results from the Phase II Clinical Trial of BC-819 and BCG in Patients With Bladder Cancer

Nov. 15, 2017 (GLOBE NEWSWIRE) -- BioCancell Therapeutics (TASE:BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer, announced today additional final…

Continue Reading BioCanCell Announces Updated Results from the Phase II Clinical Trial of BC-819 and BCG in Patients With Bladder Cancer